The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...

The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind ...

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...